Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry

Full text
Author(s):
Show less -
Shimizu, Jacqueline Farinha [1, 2] ; Lima, Caroline Sprengel [3] ; Pereira, Carina Machado [1] ; Bittar, Cintia [1] ; Batista, Mariana Nogueira [1] ; Nazare, Ana Carolina [3] ; Polaquini, Carlos Roberto [3] ; Zothner, Carsten [4, 5] ; Harris, Mark [4, 5] ; Rahal, Paula [1] ; Regasini, Luis Octavio [3] ; Gomes Jardim, Ana Carolina [1, 2]
Total Authors: 12
Affiliation:
[1] Sao Paulo State Univ, IBILCE, Genom Study Lab, Sao Jose Do Rio Preto, SP - Brazil
[2] Univ Fed Uberlandia, ICBIM, Inst Biomed Sci, Lab Virol, Uberlandia, MG - Brazil
[3] Sao Paulo State Univ, IBILCE, Lab Green & Med Chem, Sao Jose Do Rio Preto, SP - Brazil
[4] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire - England
[5] Univ Leeds, Sch Mol & Cellular Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire - England
Total Affiliations: 5
Document type: Journal article
Source: SCIENTIFIC REPORTS; v. 7, NOV 23 2017.
Web of Science Citations: 3
Abstract

Hepatitis C virus (HCV) is one of the leading causes of liver diseases and transplantation worldwide. The current available therapy for HCV infection is based on interferon-alpha, ribavirin and the new direct-acting antivirals (DAAs), such as NS3 protease and NS5B polymerase inhibitors. However, the high costs of drug design, severe side effects and HCV resistance presented by the existing treatments demonstrate the need for developing more efficient anti-HCV agents. This study aimed to evaluate the antiviral effects of sorbifolin (1) and pedalitin (2), two flavonoids from Pterogyne nitens on the HCV replication cycle. These compounds were investigated for their anti-HCV activities using genotype 2a JFH-1 subgenomic replicons and infectious virus systems. Flavonoids 1 and 2 inhibited virus entry up to 45.0% and 78.7% respectively at non-cytotoxic concentrations. The mechanism of the flavonoid 2 block to virus entry was demonstrated to be by both the direct action on virus particles and the interference on the host cells. Alternatively, the flavonoid 1 activity was restricted to its virucidal effect. Additionally, no inhibitory effects on HCV replication and release were observed by treating cells with these flavonoids. These data are the first description of 1 and 2 possessing in vitro anti-HCV activity. (AU)

FAPESP's process: 12/01403-9 - Study of “The role of Hepatitis C Virus proteins ín “The development of hepatocarcinoma
Grantee:Cintia Bittar Oliva
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 13/03897-1 - Activity of toxins Venom of Crotalus durissus terrificus ín HCV replication
Grantee:Jacqueline Farinha Shimizu
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 14/22198-0 - Therapeutic potential of Flavonoid-like drugs on Hepatitis C virus infection
Grantee:Paula Rahal
Support type: Regular Research Grants
FAPESP's process: 14/05445-3 - Anti-HCV activity of Sorfifolin, Pedalitin ánd their Pearacetylated derivatives
Grantee:Caroline Sprengel Lima
Support type: Scholarships in Brazil - Scientific Initiation